SCHEDULE: CVI Investments & Heights Capital Report 6.9% Stake in Plus Therapeutics
Beneficial Ownership Report
CVI Investments, Inc. and Heights Capital Management, Inc. have jointly reported a beneficial ownership of 6.9% in Plus Therapeutics, Inc., totaling 12,368,423 shares.
Summary
- CVI Investments, Inc. and Heights Capital Management, Inc. (collectively, "Reporting Persons") have filed a Schedule 13G regarding their beneficial ownership in Plus Therapeutics, Inc.
- The Reporting Persons collectively beneficially own 12,368,423 shares of Plus Therapeutics, Inc. common stock, $0.001 par value per share.
- This ownership represents 6.9% of the total 178,371,232 outstanding common shares of Plus Therapeutics, Inc. as of the completion of a recent offering.
- Heights Capital Management, Inc. acts as the investment manager for CVI Investments, Inc., exercising shared voting and dispositive power over these shares.
- The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Plus Therapeutics, Inc.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of beneficial ownership, not containing performance or forward-looking statements from the issuer. The presence of an institutional investor can be seen as a minor positive.
Positives
- A significant institutional investment firm, Heights Capital Management, Inc., through CVI Investments, Inc., holds a substantial stake, potentially signaling confidence in Plus Therapeutics, Inc.
Management Comments
- "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."
Industry Context
This filing indicates a significant institutional investor's position in Plus Therapeutics, Inc. Such disclosures are common in the investment landscape, reflecting portfolio adjustments or new strategic investments by funds. The mention of a recent offering suggests the stake might be related to participation in a capital raise.
Related Party Transactions
- Heights Capital Management, Inc. serves as the investment manager for CVI Investments, Inc., and has been granted a Limited Power of Attorney to enter into transactions on behalf of CVI Investments, Inc. This defines their operational relationship regarding the reported shares.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake (6.9%) by CVI Investments, Inc. and Heights Capital Management, Inc. provides transparency regarding the company's ownership structure and could influence investor perception and confidence.
Key Dates
| Date | Description |
|---|---|
| 2015-07-16 | Date of Limited Power of Attorney agreement between CVI Investments, Inc. and Heights Capital Management, Inc. |
| 2026-01-14 | Date of event which required the filing of this statement, coinciding with the filing of Plus Therapeutics, Inc.'s Prospectus (Registration No. 333-292637) and completion of an offering. |
| 2026-01-22 | Date of signing the Schedule 13G and Joint Filing Agreement by Sarah Travis on behalf of CVI Investments, Inc. and Heights Capital Management, Inc. |
Keywords
Plus Therapeutics, CVI Investments, Heights Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.